search
Back to results

A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

Primary Purpose

Indolent B-Cell Non-Hodgkin Lymphoma

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
BI-1206
Sponsored by
BioInvent International AB
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Indolent B-Cell Non-Hodgkin Lymphoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Are ≥ 18 years of age by initiation of study treatment.
  • Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL3B), MCL and marginal zone lymphoma (MZL).
  • Have measureable nodal disease
  • Are willing to undergo lymph node biopsies or biopsies of other involved tissue
  • Have relapsed disease or disease refractory to conventional treatment or for which no standard therapy exists.
  • Have received at least one line of conventional previous therapy which must include at least one rituximab-based regimen.
  • Have a life expectancy of at least 12 weeks
  • Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
  • Have CD20+ malignancy
  • Have hematological and biochemical indices within prespecified ranges

Exclusion Criteria:

  • Have had an allogenic bone marrow or stem cell transplant within 12 months
  • Have presence of active chronic graft versus host disease
  • Have current leptomeningeal lymphoma or compromise of the central nervous system.
  • Have transformed lymphoma from a pre-existing indolent lymphoma.
  • Have Waldenstrom's Macroglobulinemia or FL3B,
  • Need systemic doses of prednisolone >10 mg daily (or equipotent doses of other corticosteroids) while on the study trial other than as pre-medication.
  • Have known or suspected hypersensitivity to rituximab or BI-1206.
  • Have cardiac or renal amyloid light-chain amyloidosis.
  • Have received the following:
  • Chemotherapy or small molecule products with 2 weeks of first dose of BI-1206
  • Radiotherapy (except for focal symptomatic control of lymphadenopathy) within 4 weeks
  • Immunotherapy within 8 weeks
  • Have ongoing toxic manifestations of previous treatments.
  • Have the ability to become pregnant (or already pregnant or lactating/breastfeeding).
  • Have had major surgery from which the subject has not yet recovered.
  • Are at high medical risk because of non-malignant systemic disease including active infection on treatment with antibiotics, antifungals or antivirals.
  • Are serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV).
  • Have an active, known or suspected autoimmune disease.
  • Have concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA]),
  • Have current malignancies of other types

Sites / Locations

  • Emory University HospitalRecruiting
  • Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405Recruiting
  • Krankenhaus Nordwest Klinik für Onkologie und Hämatologie
  • Robert Bosch Hospital, Dep of Hematology, Oncology and Palliative care
  • Szpital Specjlistyczny
  • Małopolskie Centrum Medyczne
  • Hospital ICO, Trias i PujolRecruiting
  • Hospital de la Santa Creu i Sant Pau, Dep HematologiaRecruiting
  • Hospital Universitari Vall d'HebronRecruiting
  • Institut Català d'Oncologia, L'Hospitalet de LlobregatRecruiting
  • Hospital General Universitario Gregorio Marañon-Oncología MédicaRecruiting
  • Hospital Universitario HM San Chinarro
  • University Hospital Fundacion Jimenez DiazRecruiting
  • Hospital Universitario Virgen de la Arrixaca
  • Hospital Virgen Macarene
  • Department of Oncology, Skåne University HospitalRecruiting
  • Department of Oncology, Academical Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

BI-1206 IV

BI-1206 SC

Arm Description

BI-1206 IV Standard 3+3 Dose-Escalation Design

BI-1206 SC Adaptive Dose Escalation Design (Bayesian logistic regression model (BLRM)

Outcomes

Primary Outcome Measures

Documenting AEs and SAEs and determining causality in relation to BI-1206 and/or rituximab
Assess the safety and tolerability profile of BI-1206 when administered intravenously (IV) or subcutaneously (SC) in combination with rituximab in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL),subtypes follicular lymphoma (FL)(except FLgrade 3B), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL).
Determining the MTD of BI-1206 at the same dose level experiencing a BI-1206 or Rituximab-related or possibly related dose-limiting toxicity (DLT)
Select the recommended Phase 2 dose (RP2D) by establishing the maximum tolerated dose (MTD) of BI-1206 given once weekly for 4 weeks, via IV infusion or SC injection in combination with rituximab.

Secondary Outcome Measures

Evaluation of PK parameters for BI-1206.
Study the PK profile of BI-1206 when administered IV or SC in combination with rituximab in subjects with relapsed or refractory B-cell NHL, subtypes FL (except FL grade 3B), MZL and MCL.
Evaluation of PK parameters for rituximab during the BI-1206 treatment period.
Study the PK profile of rituximab when administered in combination with BI-1206 (IV or SC).
Evaluation of ADA response to BI 1206.
Assess the immunogenicity of BI-1206 when administered IV or SC in combination with rituximab.
Measurement of B cell depletion.
Evaluate the effect of BI-1206 administered IV or SC in combination with rituximab on the depletion of B-cells.
Assessment of overall response rate (ORR) according to the response criteria for malignant lymphoma (Cheson, 2014).
Assess possible anti-tumor activity of BI-1206 administered IV or SC in combination with rituximab at Week 6 after first dose of BI-1206 and for subjects who continue during maintenance therapy.
CD32b protein expression levels
Investigate CD32b protein expression levels; evaluate any potential correlation with clinical responses.

Full Information

First Posted
May 17, 2018
Last Updated
March 7, 2023
Sponsor
BioInvent International AB
search

1. Study Identification

Unique Protocol Identification Number
NCT03571568
Brief Title
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Official Title
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcYRIIB), in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 16, 2018 (Actual)
Primary Completion Date
September 22, 2025 (Anticipated)
Study Completion Date
September 22, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
BioInvent International AB

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination with Rituximab in Subjects with Indolent B-Cell Non-Hodgkin Lymphoma That has Relapsed or is Refractory to Rituximab
Detailed Description
This is a Phase 1/2a, dose escalation, consecutive-cohort, open-label trial of BI-1206 in combination with rituximab in subjects with indolent relapsed or refractory B-cell NHL, subtypes FL (except FL grade 3B), MZL, and MCL. The trial consists of 2 main parts: Phase 1 with two different Arms assessing IV or SC dosing of BI-1206,with dose escalation cohorts and selection of the RP2D of IV dosing (ivRP2D)and the RP2D of SC dosing (scRP2D) of BI-1206 in combination with rituximab (administered IV). Phase 2a with two expansion cohorts evaluating the ivRP2D and scRP2D of BI-1206 in combination with rituximab (administered IV). Subjects in each phase (Phase 1 and 2a) and dosing Arms will receive 1 cycle of induction therapy with BI-1206 in combination with rituximab. Subjects who show clinical benefit (complete response [CR], partial response [PR], or stable disease [SD]) at Week 6 will continue onto maintenance therapy and receive BI-1206 ( using the same dose and route of administration as induction therapy) and rituximab once every 8 weeks (relative to previous maintenance dose) for up to 6 maintenance cycles, or up to 1 year from first dose of BI-1206 (whichever occurs first).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Indolent B-Cell Non-Hodgkin Lymphoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Single Group Assignment
Model Description
Phase 1/2a, dose escalation, consecutive-cohort, open-label study trial of BI-1206 in combination with rituximab
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
98 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
BI-1206 IV
Arm Type
Experimental
Arm Description
BI-1206 IV Standard 3+3 Dose-Escalation Design
Arm Title
BI-1206 SC
Arm Type
Experimental
Arm Description
BI-1206 SC Adaptive Dose Escalation Design (Bayesian logistic regression model (BLRM)
Intervention Type
Biological
Intervention Name(s)
BI-1206
Other Intervention Name(s)
Rituximab
Intervention Description
375 mg/m2, as per SmPC
Primary Outcome Measure Information:
Title
Documenting AEs and SAEs and determining causality in relation to BI-1206 and/or rituximab
Description
Assess the safety and tolerability profile of BI-1206 when administered intravenously (IV) or subcutaneously (SC) in combination with rituximab in subjects with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL),subtypes follicular lymphoma (FL)(except FLgrade 3B), marginal zone lymphoma (MZL), and mantle cell lymphoma (MCL).
Time Frame
During the 28-day treatment period on induction therapy
Title
Determining the MTD of BI-1206 at the same dose level experiencing a BI-1206 or Rituximab-related or possibly related dose-limiting toxicity (DLT)
Description
Select the recommended Phase 2 dose (RP2D) by establishing the maximum tolerated dose (MTD) of BI-1206 given once weekly for 4 weeks, via IV infusion or SC injection in combination with rituximab.
Time Frame
During the 28-day treatment period on induction therapy
Secondary Outcome Measure Information:
Title
Evaluation of PK parameters for BI-1206.
Description
Study the PK profile of BI-1206 when administered IV or SC in combination with rituximab in subjects with relapsed or refractory B-cell NHL, subtypes FL (except FL grade 3B), MZL and MCL.
Time Frame
Up to 1 year
Title
Evaluation of PK parameters for rituximab during the BI-1206 treatment period.
Description
Study the PK profile of rituximab when administered in combination with BI-1206 (IV or SC).
Time Frame
Up to 1 year
Title
Evaluation of ADA response to BI 1206.
Description
Assess the immunogenicity of BI-1206 when administered IV or SC in combination with rituximab.
Time Frame
Up to 1 year
Title
Measurement of B cell depletion.
Description
Evaluate the effect of BI-1206 administered IV or SC in combination with rituximab on the depletion of B-cells.
Time Frame
Up to 1 year
Title
Assessment of overall response rate (ORR) according to the response criteria for malignant lymphoma (Cheson, 2014).
Description
Assess possible anti-tumor activity of BI-1206 administered IV or SC in combination with rituximab at Week 6 after first dose of BI-1206 and for subjects who continue during maintenance therapy.
Time Frame
Up to 1 year
Title
CD32b protein expression levels
Description
Investigate CD32b protein expression levels; evaluate any potential correlation with clinical responses.
Time Frame
Up to 1 year
Other Pre-specified Outcome Measures:
Title
Measurement of PROs using the PRO-CTCAE questionnaire.
Description
Evaluate patient-reported outcomes (PROs)in subjects receiving BI-1206
Time Frame
Up to 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Are ≥ 18 years of age by initiation of study treatment. Have B-cell NHL proven by histology, with histological subtypes limited to follicular lymphoma (FL) (except FL grade 3B), MCL and marginal zone lymphoma (MZL). Have measurable nodal disease Are willing to undergo lymph node biopsies or biopsies of other involved tissue Have relapsed disease or disease refractory to conventional treatment or for which no standard therapy exists. Have received at least one line of conventional previous therapy which must include at least one rituximab-based regimen. Have a life expectancy of at least 12 weeks Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. Have CD20+ malignancy Have hematological and biochemical indices within prespecified ranges Exclusion Criteria: Have had an allogenic bone marrow or stem cell transplant within 12 months Have presence of active chronic graft versus host disease Have current leptomeningeal lymphoma or compromise of the central nervous system. Have transformed lymphoma from a pre-existing indolent lymphoma. Have Waldenstrom's Macroglobulinemia or FL3B, Need systemic doses of prednisolone >10 mg daily (or equipotent doses of other corticosteroids) while on the study trial other than as pre-medication. Have known or suspected hypersensitivity to rituximab or BI-1206. Have cardiac or renal amyloid light-chain amyloidosis. Have received any of the following: Chemotherapy or small molecule products with 2 weeks of first dose of BI-1206 Radiotherapy (except for focal symptomatic control of lymphadenopathy) within 4 weeks Immunotherapy within 8 weeks Have ongoing toxic manifestations of previous treatments. Have the ability to become pregnant (or already pregnant or lactating/breastfeeding). Have had major surgery from which the subject has not yet recovered. Are at high medical risk because of non-malignant systemic disease including active infection on treatment with antibiotics, antifungals or antivirals. Are serologically positive for hepatitis B, hepatitis C or human immunodeficiency virus (HIV). Have an active, known or suspected autoimmune disease. Have concurrent congestive heart failure, prior history of class III/ IV cardiac disease (New York Heart Association [NYHA]), Have current malignancies of other types
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Sanjay Patel
Phone
+46734155539
Email
sanjay.patel@bioinvent.com
First Name & Middle Initial & Last Name or Official Title & Degree
Andres McAllister, MD, PhD
Email
andres.mcallister@bioinvent.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mats Jerkeman, MD PhD
Organizational Affiliation
Senior Consultant and Adjunct Professor, Skane Univ Hospital, Lund, Sweden
Official's Role
Principal Investigator
Facility Information:
Facility Name
Emory University Hospital
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jonathon Cohen, MD
Facility Name
Norton Cancer Institute - St. Matthews 3991 Dutchmans Lane Medical Plaza II, Suite 405
City
Louisville
State/Province
Kentucky
ZIP/Postal Code
40207
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Don Stevens, MD
Facility Name
Krankenhaus Nordwest Klinik für Onkologie und Hämatologie
City
Frankfurt
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eckhart Weidmann, MD
Facility Name
Robert Bosch Hospital, Dep of Hematology, Oncology and Palliative care
City
Stuttgart
Country
Germany
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicola Giesen, MD
Facility Name
Szpital Specjlistyczny
City
Grudziadz
ZIP/Postal Code
86-300
Country
Poland
Individual Site Status
Terminated
Facility Name
Małopolskie Centrum Medyczne
City
Krakow
Country
Poland
Individual Site Status
Terminated
Facility Name
Hospital ICO, Trias i Pujol
City
Badalona
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Juan Manuel Sancho Cia, MD
Facility Name
Hospital de la Santa Creu i Sant Pau, Dep Hematologia
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Silvana Novelli, MD
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pablo Abrisqueta Costa, MD
Facility Name
Institut Català d'Oncologia, L'Hospitalet de Llobregat
City
Barcelona
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Eva Domingo Domenech, MD
Facility Name
Hospital General Universitario Gregorio Marañon-Oncología Médica
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mariana Bastos Oreiro, MD
Facility Name
Hospital Universitario HM San Chinarro
City
Madrid
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jaime Perez de Oteyza, MD
Facility Name
University Hospital Fundacion Jimenez Diaz
City
Madrid
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Raul Cordoba Mascunano, MD
Facility Name
Hospital Universitario Virgen de la Arrixaca
City
Murcia
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joaquin Gomez Espuch, MD
Facility Name
Hospital Virgen Macarene
City
Seville
Country
Spain
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Isabel Fernández Román, MD
Facility Name
Department of Oncology, Skåne University Hospital
City
Lund
ZIP/Postal Code
SE-22185
Country
Sweden
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mats Jerkeman, PI
First Name & Middle Initial & Last Name & Degree
Mats Jerkeman, MD, PhD
Facility Name
Department of Oncology, Academical Hospital
City
Uppsala
ZIP/Postal Code
751 85
Country
Sweden
Individual Site Status
Terminated

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
All information concerning the product as well as any matter concerning the operation of the Sponsor, such as clinical indications for the drug, its formula, methods of manufacture and other scientific data relating to it, that have been provided by the Sponsor and are unpublished, are confidential and must remain the sole property of the Sponsor. The Investigator will agree to use the information only for the purposes of carrying out this study and for no other purpose unless prior written permission from the Sponsor is obtained.
IPD Sharing Time Frame
Within one year from end of study
IPD Sharing Access Criteria
Paper copy of CSR

Learn more about this trial

A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma

We'll reach out to this number within 24 hrs